Loading
CytoDyn Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Naydenov Jordan G, was filed 03 Nov 2020.
CytoDyn Inc.: what insiders have been doing
This page follows insider dealings at CytoDyn Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for CytoDyn Inc. The previous disclosure was published on 14 February 2023.
Our records for CytoDyn Inc. go back to 2007, with 18 purchases and 45 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
293
Thresholds
n/a
Buy Volume
€3M
18 ops. · all time
Sell Volume
€31M
45 ops. · all time
Since the insiders bought
- -56.3%Entry US$2.70 · Close at T+365 US$1.18
- -47.8%Entry US$2.49 · Close at T+365 US$1.30
- -11.1%Entry US$0.72 · Close at T+365 US$0.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2026FY ended May 2026 · cache
US$0.23
Analyst consensus
Income statement
Gross profitUS$183.4k
EBITDA-US$40.2M
Net income-US$44.2M0.0% margin
Valuation
Beta1.50
Balance sheet & cash
Market capUS$338M
Total debtUS$27.3M
Free Cash Flow-US$17.3M
Profitability & ownership
ROA-95.2%
% insiders0.0%
% institutions0.0%
Last declaration on 14 February 2023
Declarations293 total
434,782 sharesCommon StockSEC:0001104659-23-022094:0
16,927 shares0Common StockSEC:0001104659-22-123365:0
12,008 shares0Common StockSEC:0001104659-22-123366:0
15,234 shares0Common StockSEC:0001104659-22-119979:0
10,807 shares0Common StockSEC:0001104659-22-119981:0
13,671 shares0Common StockSEC:0001104659-22-119978:0
16,084 shares0Common StockSEC:0001104659-22-114098:0
12,714 shares0Common StockSEC:0001104659-22-114100:0
17,922 shares0Common StockSEC:0001104659-22-114101:0
9,824 shares0Common StockSEC:0001104659-22-109690:0
13,849 shares0Common StockSEC:0001104659-22-109687:0
12,428 shares0Common StockSEC:0001104659-22-109693:0
10,292 shares0Common StockSEC:0001104659-22-105981:0
18,793 shares0Common StockSEC:0001104659-22-105980:0
13,020 shares0Common StockSEC:0001104659-22-105983:0
646,552 shares0Common StockSEC:0001104659-22-102416:0
8,965 shares0Common StockSEC:0001104659-22-101254:0
9,457 shares0Common StockSEC:0001104659-22-101258:0
7,086 shares0Common StockSEC:0001104659-22-101256:0
10,516 shares0Common StockSEC:0001104659-22-097602:0
11,094 shares0Common StockSEC:0001104659-22-097603:0
8,313 shares0Common StockSEC:0001104659-22-097604:0
6,588 shares0Common StockSEC:0001104659-22-092175:0
5,208 shares0Common StockSEC:0001104659-22-092173:0
6,950 shares0Common StockSEC:0001104659-22-092174:0
25 of 293 declarations
About CytoDyn Inc.
Geographically, CytoDyn operates primarily from the United States and maintains its headquarters in Vancouver, Washington. The company’s development work is centered on U.S. clinical and regulatory pathways, with academic collaborations involving U.S. research institutions. Recent milestones matter for market perception: new oncology data were presented in 2026, an investor webcast was held on April 30, 2026, and the company publicly discussed ongoing phase 2 colorectal cancer work and planned phase 2 mTNBC activity. For investors in France, Belgium, and Switzerland, CytoDyn should be viewed as a speculative clinical-stage biotech with a single dominant scientific thesis, significant upside optionality if its CCR5/leronlimab program succeeds, and substantial execution risk if clinical or regulatory readouts disappoint.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
